Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PTGES | O14684 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777748 | 0.86 | MAPT (0.67) | MAPTLMNASMN1; SMN2BCHECYP1A2 | |
| SCHEMBL3771748 | 0.85 | PTGES (0.69) | MAPTLMNASMN1; SMN2BCHECYP1A2 | |
| SCHEMBL3778640 | 0.84 | RHOC (0.57) | MAPTLMNASMN1; SMN2BCHEKCNK3 | |
| SCHEMBL3771262 | 0.82 | MAPT (0.71) | MAPTLMNASMN1; SMN2BCHECYP1A2 | |
| SCHEMBL3774815 | 0.81 | TP53 (0.58) | MAPTLMNASMN1; SMN2BCHEPKM | |
| SCHEMBL3774731 | 0.81 | MAPT (0.54) | MAPTLMNASMN1; SMN2BCHEMEN1 | |
| SCHEMBL3779966 | 0.81 | MAPT (0.54) | MAPTLMNASMN1; SMN2BCHEMEN1 | |
| SCHEMBL3771548 | 0.81 | BCHE (0.68) | MAPTLMNASMN1; SMN2BCHEMEN1 | |
| SCHEMBL3765642 | 0.79 | MAPT (0.69) | MAPTLMNASMN1; SMN2BCHECYP1A2 | |
| SCHEMBL3772291 | 0.78 | MAPT (0.68) | MAPTCYP1A2CYP3A4CYP2D6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677376-B1 | COMPLEXES COMPRISING ROTAMASE INHIBITORS AND CYCLOPHILINS, ADMINISTERED FOR PREVENTION OF NEURODEGENARATIVE DISEASES SUCH AS PARKINSON'S OR ALZHEIMER'S DISEASE | GUILFORD PHARMACEUTICALS, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030232815-A1 | Non-peptidic cyclophilin binding compounds and their use | HAMILTON GREGORY S (US) | 2003-12-18 | — | — | US | disclosed |
| US-6593362-B2 | Medical conditions involving breakdown of mitochondrial energy metabolism induced by calcium overload, in treating alopecia and promoting hair growth, in treating infections with filarial and helmintic parasites, and in treating and | GUILFORD PHARMACEUTICALS INC. | 2003-07-15 | — | — | US | disclosed |
| US-20030055009-A1 | Non-peptidic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS, INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055009-A1 | Non-peptidic cyclophilin binding compounds and their use | PPIF, HSPE1, PPIG | MAPT 1353/4885LMNA 3215/4885SMN1; SMN2 4286/4885 |
| US-20030232815-A1 | Non-peptidic cyclophilin binding compounds and their use | GAP43, PPIG, FKBP14 | MAPT 392/4885LMNA 3001/4885SMN1; SMN2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.